SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration

被引:1
|
作者
Han, Lin [1 ]
Liang, Xiao-Hua [2 ]
Chen, Li-Xin [1 ]
Bao, Shi-Min [1 ]
Yan, Zhi-Qiang [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Ctr Expt Anim, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Oncol, Shanghai 200433, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2013年 / 6卷 / 11期
关键词
Non-small cell lung cancer; brain metastasis; RNAi screening; epigenetics; SIRT1; TO-MESENCHYMAL TRANSITION; RADIATION-THERAPY; INVASION; TRANSCRIPTION; PROGRESSION; CARCINOMA; REPRESSION; CORTACTIN; PATHWAY; DISEASE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Brain metastases are a frequent and ongoing major complication of non-small cell lung cancer (NSCLC). To deepen our understanding to the underlying mechanisms by which NSCLC cells metastasize to brain and hence to improve the therapy, a high throughput RNAi screening with shRNA library of 153 epigenetic genes was subjected to A549, a NSCLC cell line with high migration ability, to examine the effects of these genes on cell migration by wound-healing assay. The screening results showed that knockdown of 2 genes (KDM5B and SIRT1) dramatically and specifically inhibits A549 migration but not affects the proliferation, which was subsequently confirmed through transwell migration assay. Furthermore, SIRT1 is found to be highly expressed in brain metastasis tissues of NSCLC, compared to the NSCLC tissues, suggesting that SIRT1 may play roles in brain metastasis of NSCLC. The relationship between SIRT1 expression and cell migration ability was further investigated in three NSCLC cell lines and the result indicated that SIRT1 expression is tightly correlated with cell migration ability. Collectively, our work provides potential biomarker and therapeutic target for brain metastasis of NSCLC.
引用
收藏
页码:2357 / +
页数:11
相关论文
共 50 条
  • [21] ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
    Yu, Zhi-Qiong
    Wang, Meng
    Zhou, Wen
    Mao, Meng-Xia
    Chen, Yuan-Yuan
    Li, Na
    Peng, Xiao-Chun
    Cai, Jun
    Cai, Zhi-Qiang
    JOURNAL OF DRUG TARGETING, 2022, 30 (08) : 845 - 857
  • [22] XCR1 promotes cell growth and migration and is correlated with bone metastasis in non-small cell lung cancer
    Wang, Ting
    Han, Shuai
    Wu, Zhipeng
    Han, Zhitao
    Yan, Wangjun
    Liu, Tielong
    Wei, Haifeng
    Song, Dianwen
    Zhou, Wang
    Yang, Xinghai
    Xiao, Jianru
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 464 (02) : 635 - 641
  • [23] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [24] Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice
    Koyi, Hirsh
    Hillerdal, Gunnar
    Kolbeck, Karl-Gustav
    Brodin, Daniel
    Liv, Per
    Branden, Eva
    ANTICANCER RESEARCH, 2016, 36 (10) : 5397 - 5402
  • [25] Hypoxic markers in non-small cell lung cancer (NSCLC) - A review
    Xu, F. -X.
    Zhang, Y. -L.
    Liu, J. -J.
    Zhang, D. -D.
    Chen, H. -B.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (05) : 849 - 852
  • [26] Prognostic Factors for Brain Metastasis in Non-Small Cell Lung Cancer
    Duma, Narjust
    Sanchez, Laysa
    Miranda, Claudia
    Glisch, Chad
    Abu-Ihweij, Khaleb
    Zhang, Shijia
    Osorio, Carlos
    Listo, Matthew
    Harper, Harry D.
    Gutierrez, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S535 - S535
  • [27] GAP43, a novel metastasis promoter in non-small cell lung cancer
    Zhang, Fanrong
    Ying, Lisha
    Jin, Jiaoyue
    Feng, Jianguo
    Chen, Kaiyan
    Huang, Minran
    Wu, Yingxue
    Yu, Herbert
    Su, Dan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [28] miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1
    Ye, Zaiting
    Fang, Bingmu
    Pan, Jiongwei
    Zhang, Ning
    Huang, Jinwei
    Xie, Congying
    Lou, Tianzheng
    Cao, Zhuo
    ONCOLOGY REPORTS, 2017, 37 (06) : 3244 - 3252
  • [29] Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)
    Mascaux, Celine
    Ekman, Simon
    Dooms, Christophe
    Shepherd, Frances A.
    CURRENT PULMONOLOGY REPORTS, 2013, 2 (01) : 1 - 9
  • [30] Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales
    Crook, A
    Duffy, A
    Girling, DJ
    Souhami, RL
    Parmar, MKB
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) : 1552 - 1558